Press Releases

    INCLINE VILLAGE, Nev. , Jan. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present at the 30th Annual JP Morgan Healthcare Conference in San Francisco on Thursday,

INCLINE VILLAGE, Nev. , Jan. 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the expiration and preliminary results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a

INCLINE VILLAGE, Nev. , Dec. 19, 2011 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2011 of approximately $72 million , as compared with actual results of $76 million for the fourth quarter of 2010, a five

INCLINE VILLAGE, Nev. , Dec. 15, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 15, 2011 , regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 8, 2011 , the record date.

INCLINE VILLAGE, Nev. , Dec. 12, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Christine Larson has resigned her position as vice president and chief financial officer of PDL effective as of December 9 , 2011.  The company will immediately begin a search for a

INCLINE VILLAGE, Nev. , Dec. 12, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 ( February 2015 Notes), to 155.396 shares of common stock per $1,000 principal

INCLINE VILLAGE, Nev. , Dec. 7, 2011 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 ( February 2015 Notes) is 155.354 shares of common stock per $1,000 principal amount or

INCLINE VILLAGE, Nev. , Nov. 15, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced it has commenced an offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like

INCLINE VILLAGE, Nev. , Nov. 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2011 . (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Revenues Total revenues for the third quarter of 2011 were

INCLINE VILLAGE, Nev. , Nov. 8, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference next week in New York City .

INCLINE VILLAGE, Nev. , Nov. 2, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2011 , on Wednesday, November 9, 2011 , after the markets close.

PDL BioPharma Retains Franklin Berger and Dr. Evan Bedil as Advisors to Assist with Implementation of Royalty Acquisition Strategy INCLINE VILLAGE, Nev., Oct. 19, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has retained Franklin M.

PDL BioPharma Completes Regular Quarterly Dividend Payment INCLINE VILLAGE, Nev., Sept. 15, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 15, 2011, regular quarterly dividend payment of $0.15 per share to all stockholders

PDL BioPharma to Present at Upcoming Investor Conferences INCLINE VILLAGE, Nev., Sept. 13, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the following upcoming

PDL BioPharma Provides Third Quarter 2011 Revenue Guidance of $83 Million INCLINE VILLAGE, Nev., Sept. 8, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2011 , of approximately $83 million , as